Biotech company PharmAust (ASX: PAA) has officially begun recruitment for the phase IIb trial of its lead anti-cancer drug monepantel (MPL) on canine lymphoma and has put a call out for more dogs to participate. The trial will test the effects of MPL upon pet owners’ dogs with treatment-naïve B cell lymphoma – that is, dogs that have not undergone any treatment for this cancer. PharmAust today confirmed “several” dogs have been successfully recruited and have started treatment with MPL tablets. Meanwhile, six other dogs that were not eligible for the trial have commenced treatment with the tablets on a...